Brand  (β version)

PDB ID: 4FOD

Hetero Atom Contents

  The number of atoms exceeds 100,000.
  So, it can not be displayed here.

Select unit:

Select hetatm:   

close
information
centroid:
interaction residue:

Select chain:   Sequence  

Data format:   

Color scheme of protein:

Ligands
Code Name Style Show Link
0UV 4-fluoro-N-{(2e)-6-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-1-[cis-4-(propan-2-ylcarbamoyl)cyclohexyl]-1,3-dihydro-2h-benzimidazol-2-ylidene}benzamide PoSSuM
GOL Glycerol PoSSuM
Non-standard Residues
Code Name Show
Glycosylation
Code Name Emphasize
Modification
Code Name Show

Structure summary

Code : 4FOD   PDBj   RCSB PDB   PDBe
Header : Transferase/Inhibitor
Title : Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 36
Release Data : 2012-07-11
Compound :
mol_id molecule chains synonym
1 ALK tyrosine kinase receptor A Anaplastic lymphoma kinase
ec: 2.7.10.1
fragment: Kinase domain, unp residues 1078-1410
mutation: C1097S
Source :
mol_id organism_scientific organism_common expression_system
1 Homo sapiens  (taxid:9606) Human Spodoptera frugiperda  (taxid:7108)
gene: ALK
expression_system_vector_type: baculovirus
Authors : Whittington, D.A., Epstein, L.F., Chen, H.
Keywords : receptor tyrosine kinase, inhibitor, crizotinib, neuroblastoma, CD246, phosphotransferase, NPM-ALK, EML4-ALK, Transferase-Inhibitor complex
Exp. method : X-RAY DIFFRACTION ( 2.00 Å )
Citation :

The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer.

Lewis, R.T.,Bode, C.M.,Choquette, D.M.  et al.
(2012)  J.Med.Chem.  55 : 6523 - 6540

PubMed: 22734674
DOI: 10.1021/jm3005866

Reaction

Chain : A
UniProt : Q9UM73 (ALK_HUMAN)
Reaction: EC: Evidence:
Physiological Direction:
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) 2.7.10.1 PROSITE-ProRule:PRU10028, PubMed:30061385, PubMed:34819673
-